Inuxair

Beclometasone dipropionate, the active ingredient in Inuxair, is a corticosteroid presented as an inhalation aerosol (pressurised metered‑dose inhaler) for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) as maintenance therapy in adults and adolescents. GNH USA supplies Inuxair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inuxair combines a corticosteroid and a long‑acting β2‑agonist to provide maintenance therapy for obstructive airway diseases.

Asthma: reduces airway inflammation and improves symptom control. COPD: decreases exacerbations and enhances lung function. Exercise‑induced bronchoconstriction: offers prophylactic bronchodilation for activity‑related symptoms.

Common Side Effects: - Oral thrush or candidiasis - Hoarseness or voice change - Cough or throat irritation - Headache - Tremor - Dry mouth

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Adrenal suppression with prolonged use - Pneumonia or respiratory infection - Cardiac arrhythmia or tachycardia - Significant hypokalemia

Before using Inuxair, consider the following precautions: - Assess inhaler technique: ensure correct use to achieve optimal dosing. - Monitor for oral candidiasis: rinse mouth after each inhalation. - Screen for cardiovascular disease: β2‑agonist may affect heart rate and rhythm. - Use the lowest effective dose: minimize systemic corticosteroid exposure. - Avoid use in patients with known hypersensitivity to any component. - Store at room temperature: keep inhaler in original pack, protect from moisture and heat.

Inuxair may interact with other medicines as follows:

Major Interactions (Avoid): - Beta‑blockers: can reduce bronchodilator effectiveness and precipitate bronchospasm. - MAO inhibitors or tricyclic antidepressants: may increase cardiovascular side effects. - Diuretics: can potentiate hypokalemia caused by the β2‑agonist.

Moderate Interactions (Monitor Closely): - Other inhaled corticosteroids: increase total systemic steroid load. - CYP3A4 inhibitors (e.g., ritonavir): may raise formoterol plasma concentrations. - Theophylline: additive bronchodilator effect may increase risk of side effects.